AnaptysBio (NASDAQ:ANAB) stock maintained its Neutral rating and $19.00 price target from H.C. Wainwright. Currently trading ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $19.00 ...

Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of AnaptysBio (NasdaqGS:ANAB) with a Outperform ...

Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $36.17, accompanied by ...

Wolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating and $25 price target The stock’s current ...

Jennison Associates LLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the ...

This might drive the stock higher in the near term. The heavy selling pressure might have exhausted for AnaptysBio (ANAB) as it is technically in oversold territory now. In addition to this ...

Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of AnaptysBio's stock. This examination reveals shifts in analysts' expectations over time.

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...